Most pharmaceutical companies believe they are inspection ready.
They say it with confidence.
They point to their SOPs, their training records, their audit histories.
They prepare binders, rehearse answers, and conduct mock inspections.
And yet—when inspectors from the U.S. Food and Drug Administration arrive—many of those same companies still receive observations.
Why?
Because inspection readiness is not a moment in time. It is not a checklist. It is not something you turn on a few weeks before an audit.
Inspection readiness is a reflection of how your organization operates every single day.
The uncomfortable truth is that most systems are built to appear compliant, not to perform under scrutiny.
Procedures exist, but they are not followed consistently.
Training is completed, but understanding is shallow.
Investigations are documented, but root causes remain unresolved.
Inspectors are not looking for perfection. They are looking for consistency, clarity, and control.
They ask simple questions:
- Does the process behave as described?
- Do people understand what they are doing—and why?
- Does the data tell a coherent and trustworthy story?
When those answers don’t align, observations follow.
True inspection readiness looks different.
It shows up in operators who can explain their process without hesitation.
In deviations that are investigated with rigor—not rushed to closure.
In systems that reveal problems early, instead of hiding them.
It is not reactive. It is embedded.
And most importantly—it is visible without preparation.
If your organization relies on “getting ready” for inspections, you are not ready.
You are rehearsing.
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
